Gilead Decides On Bigger Dance Floor With Tango

Immuno-Oncology Collaboration Expands To Up To 15 Novel Targets

Gilead is making a $20m equity investment in Tango, with the biotech’s series B backers also increasing their investments.

Feet of professional tango dancers in dancing movement on bright background indoors
A discovery deal between Gilead and Tango is turning into a dance marathon

Promising early results from a target discovery collaboration with Gilead Sciences, Inc. are yielding multiple windfalls for Tango Therapeutics, Inc. – Gilead is increasing the size and scope of the original collaboration inked in 2018, it is making a $20m equity investment in Tango, and that is prompting Tango’s existing series B backers to purchase further equity to maintain their ownership proportion in the biotech.

All told, Tango gets $125m up front from Gilead in addition to the $20m investment, the partners announced 17 August....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.